Abstracts tagged "treatment and patient preferences"

Abstract Number: 2247 • 2019 ACR/ARP Annual Meeting
Patient Factors Associated with Willingness to Change Rheumatoid Arthritis Medications
Raj Vachhani¹, Lang Chen ¹, Ronan O'Beirne ², Joshua Melnick ³, Eric Ruderman ⁴, Jeffrey Curtis ¹ and Maria Danila ², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³University of Alabama at Birmingham, Birmimgham, AL, ⁴Northwestern University Feinberg School of Medicine, Division of Rheumatology, Evanston, IL
Background/Purpose: Evidence-based guidelines recommend escalation of therapy in patients with rheumatoid arthritis (RA) with inadequately controlled disease. However, some patients are hesitant to change therapies…
Abstract Number: 2266 • 2019 ACR/ARP Annual Meeting
Treatment Preferences in Patients with Axial Spondyloarthritis
Dafne Capelusnik¹, Emilce Schneeberger ², Leonela Lysseth Macias Oviedo ¹, Juan Manuel Sevillano Gutierrez ³ and Gustavo Citera ⁴, ¹Instituto de Rehabilitacion Psicofisica, CABA, Ciudad Autonoma de Buenos Aires, Argentina, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Instituto de Rehabilitacion Psicofisica, CABA, Argentina, ⁴Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Due to the increasing tendency of involving patients in decisions regarding their health care and knowing the need for further research on patients' preferences…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].